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Carbapenem-Resistant Pseudomonas
aeruginosa with Acquired blaVIM
Metallo-ß-Lactamase Determinants, Italy
To the Editor: Acquired metallo-ß-lactamase
determinants in Pseudomonas aeruginosa and
other major bacterial pathogens are of concern
for development of antimicrobial drug resistance.
The carbapenemase and extended-spectrum
cephalosporinase activity of metallo-ß-lactamases,
as well as their resistance to ß-lactamase
inhibitors, may severely limit the antimicrobial
agents active against bacterial strains that
produce such enzymes (1,2). Antimicrobial
chemotherapy may become ineffective against
P. aeruginosa strains with a multidrug-resistant
phenotype that have acquired a metallo-ß-
lactamase determinant.
We recently described a new acquired
metallo-ß-lactamase determinant, blaVIM, in a
carbapenem-resistant  P. aeruginosa clinical
isolate (VR-143/97) from the University Hospital
of Verona, Italy (3). This isolate was the index
strain of an outbreak of blaVIM-positive
P. aeruginosa, which was caused both by strains
that were clonally related to VR-143/97 and by
clonally unrelated strains (4). blaVIM is the second
known metallo-ß-lactamase determinant that
can spread among P. aeruginosa; the first was
blaIMP, which was detected in the early 1990s in
nosocomial isolates of various Enterobacteri-
aceae, P. aeruginosa, and other nonfastidious
gram-negative nonfermenters from the Far East
(1,2,5-7) and, recently, in an Acinetobacter
baumannii clinical isolate from Italy (8).
Although completely unrelated at the sequence
level, blaVIM resembles blaIMP in being carried on
an integron-borne mobile gene cassette and in
encoding an enzyme (VIM-1) with broad
substrate specificity (3). Because of these
properties, blaVIM has the potential to become a
dangerous resistance determinant.
An analysis of carbapenem-resistant
P. aeruginosa from Italian hospitals since 1998
showed production of metallo-ß-lactamase, as-
sayed as described (3), in five isolates from three
hospitals in Italy. Two isolates (PPV-97 and PPV-
108) were from the University Hospital of Pavia
(PPV-97 was isolated in September 1998 from the
urine of an inpatient in the neurosurgery
department, and PPV-108 was isolated in
November 1998 from a decubitus ulcer of an
inpatient in the vascular surgery department);
two (TS-832035 and TS-832347) were isolated in
February 1999 from the University Hospital of
Trieste (both from the blood of inpatients, in the
intensive care unit and in the internal medicine
department, respectively); and one (SAP-01/99)
was isolated in September 1999 from the Rome
University Hospital “Policlinico Umberto I” (from
the blood of an inpatient in the vascular surgery
department). Except for those from Pavia
Hospital, where the two departments share the
same surgical unit, no epidemiologic relationship
could be established among any of them or with
those previously isolated in Verona (3,4).
The five isolates were highly resistant to
carbapenems (MICs for imipenem and meropenem
were >64  µg/mL) and to carbenicillin, ticarcillin,
ticarcillin/clavulanate, piperacillin, piperacillin/
tazobactam, mezlocillin, ciprofloxacin, gentami-
cin, tobramycin, and netilmicin. All five were also
resistant to ceftazidime and cefepime, except for
SAP-01/99, which had intermediate resistance to
the above drugs. Some isolates retained
susceptibility to aztreonam (PPV-97, TS-832035,
and SAP-01/99) or amikacin (PPV-108, TS-
832035, and TS-832347).
In a colony-blot hybridization assay (3), all
the above isolates were recognized by a blaVIM-
specific probe consisting of an amplicon that
contained the entire blaVIM coding sequence (3).
None were recognized by a probe specific for
blaIMP and consisting of a 0.5-kb HindIII fragment
from the blaIMP gene (8).
Our results indicate that circulation of
carbapenem-resistant  P. aeruginosa carrying
blaVIM metallo-ß-lactamase determinants, origi-
nally detected in one Italian hospital (3-4), could
soon become widespread. The detection in
different hospitals of blaVIM-positive isolates that
apparently were epidemiologically unrelated
suggests that the environmental reservoir of
blaVIM-containing strains is relatively broad and
that this novel determinant has potential
relevance for the emerging phenomenon of
carbapenem resistance in P. aeruginosa. Since
we did not sequence the blaVIM-related genes
carried by the various isolates, we do not yet
know whether they differ from that cloned from
P. aeruginosa VR-143/97 (3). The five isolates
described in this report are being characterized to
ascertain their clonal relatedness and identify
the sequences of their blaVIM-related determi-
nants. The recent appearance of this and other
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and other gram-negative pathogens in Europe (8-
10) underlines the need for systematic surveil-
lance to monitor the spread of similar resistance
determinants.
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Malaria and Global Warming
in Perspective?
To the Editor: I read with great interest the
article “From Shakespeare to Defoe: malaria in
England in the Little Ice Age” (1). Unfortunately,
the article is not as balanced as a presentation
last year by Paul Reiter, which clearly illustrated
that, although climate is important in the
transmission of malaria, the influence of other
factors (e.g., access to medical care and improved
housing) is likely to be of more importance in
Europe.
Malaria indeed was quite common in Europe,
even in the Roman Empire and in Medieval
Europe, and until a few decades ago, it was still
present in parts of Europe, Australia, and North
America. In fact, the failure of the 1806 British
invasion of Zeeland in the Netherlands may be
attributable to infection of the British forces with
malaria. However, the authors referenced by
Reiter have never made the claim that in the
coming years warmer “temperatures will result
in malaria transmission in Europe and North
America.” On the contrary, the reports of the
Intergovernmental Panel on Climate Change
Reiter quotes conclude that “Although climate
change could increase the potential transmission
of malaria [in Europe and North America],
existing public health resources—disease sur-
veillance, surface water management, and
treatment of cases—would make reemergent
malaria unlikely” (2,3).
Reiter’s argument that some scientists
attribute the recent observed increase in malaria
risk to climate trends is also not accurate. While
acknowledging the sensitivity of the malaria
mosquito and parasite to climate, these research-
ers examine insect and incidence data to explore
multiple factors underlying malaria emergence.
Another group of scientists uses mathematical
simulation models to estimate changes in
malaria risk over the next few decades. These
models, which are heuristic tools not meant to
predict future worlds, assess how potential risk
for malaria may by affected by changes in
climate (4). The goals of both types of research
are to improve knowledge of the complex malaria
transmission cycle, define epidemic-prone areas,
identify the reasons for increased malaria risk,
and develop solutions to protect vulnerable
communities.